ProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $10.00 at HC Wainwright

ProQR Therapeutics (NASDAQ:PRQR) had its price objective hoisted by HC Wainwright from $5.00 to $10.00 in a report issued on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.

Separately, Raymond James upgraded shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price objective for the company from $6.00 to $14.00 in a research note on Tuesday, October 29th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $7.13.

ProQR Therapeutics Stock Performance

PRQR stock traded up $0.20 during trading on Friday, reaching $3.77. The company had a trading volume of 997,020 shares, compared to its average volume of 520,879. The firm has a 50-day simple moving average of $2.51 and a 200-day simple moving average of $2.10. The company has a market cap of $307.93 million, a price-to-earnings ratio of -13.00 and a beta of 0.26. ProQR Therapeutics has a twelve month low of $1.18 and a twelve month high of $4.62.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.09. ProQR Therapeutics had a negative net margin of 140.17% and a negative return on equity of 55.42%. The business had revenue of $6.79 million during the quarter, compared to analysts’ expectations of $3.32 million. Sell-side analysts expect that ProQR Therapeutics will post -0.31 earnings per share for the current year.

Hedge Funds Weigh In On ProQR Therapeutics

Several institutional investors have recently made changes to their positions in PRQR. Ikarian Capital LLC increased its holdings in ProQR Therapeutics by 2.3% in the 1st quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock worth $1,098,000 after acquiring an additional 10,958 shares in the last quarter. EP Wealth Advisors LLC purchased a new stake in ProQR Therapeutics in the 1st quarter worth $26,000. OneDigital Investment Advisors LLC increased its holdings in ProQR Therapeutics by 37.0% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 15,550 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in ProQR Therapeutics by 120.1% in the 1st quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 19,100 shares in the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in ProQR Therapeutics in the 1st quarter worth $56,000. 32.65% of the stock is owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).